| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-09-04 |
详情>>
内部人交易：
Lemaitre Dan共交易3笔
|
| 2020-08-10 |
详情>>
股本变动：
变动后总股本2065.72万股
|
| 2020-08-10 |
详情>>
业绩披露：
2020年中报每股收益-2.17美元,归母净利润-4420.8万美元,同比去年增长10.08%
|
| 2020-05-27 |
详情>>
业绩披露：
2020年一季报每股收益-0.9美元,归母净利润-1811.6万美元,同比去年增长17.76%
|
| 2020-05-11 |
财报披露：
美东时间 2020-05-11 盘后发布财报
|
| 2020-04-27 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.Proposal No. 1 - To elect two director nominees to serve as Class I directors for a three-year term expiring at the annual meeting of stockholders to be held in 2023, or until each of their respective successors is duly elected and qualified;
2.Proposal No. 2 - To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
3.Proposal No. 3 - To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.Proposal No. 4 - To approve an amendment to our Endologix, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the total number of shares of our common stock reserved for issuance under the plan by 1,000,000 shares, or from 4,130,000 shares to 5,130,000 shares;
5.Other Business - To transact such other business as may properly come before the annual meeting, or any adjournment or postponement thereof
|
| 2020-03-11 |
详情>>
业绩披露：
2017年年报每股收益-7.97美元,归母净利润-6640万美元,同比去年增长57.07%
|
| 2020-03-11 |
详情>>
业绩披露：
2019年年报每股收益-3.84美元,归母净利润-6475.7万美元,同比去年增长18.76%
|
| 2020-03-10 |
复牌提示：
2020-03-09 10:11:28 停牌，复牌日期 2020-03-09 10:21:29
|
| 2019-11-07 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-3.57美元,归母净利润-5692.7万美元,同比去年增长-5.89%
|
| 2019-08-09 |
详情>>
业绩披露：
2019年中报每股收益-3.44美元,归母净利润-4916.2万美元,同比去年增长-12.65%
|
| 2019-07-08 |
股东大会：
将于2019-08-05召开股东大会
会议内容 ▼▲
- 1.To elect three director nominees to serve as Class III directors for a three-year term expiring at the annual meeting of stockholders in 2022, or until each of their respective successors is duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
3.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To approve an amendment to our Endologix, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the total number of shares of our common stock reserved for issuance under the plan by 2,500,000 shares, or from 1,630,000 shares to 4,130,000 shares;
5.To approve an amendment to our Endologix, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to provide that the number of shares available for grant under the plan will be reduced by one share of common stock (instead of by one-and-six-tenths (1.6) shares of common stock) for each share of common stock granted under the plan pursuant to a restricted stock award, stock payment award or restricted stock unit award;
6.To approve an amendment to our Endologix, Inc. Amended and Restated 2006 Employee Stock Purchase Plan, as amended, to increase the total number of shares of our common stock reserved for issuance under the plan by 500,127 shares, or from 455,873 shares to 956,000 shares;
7.To approve the adoption of a stock option exchange program, as described in the proxy statement;
8.To transact such other business as may properly come before the annual meeting, or any adjournment or postponement thereof.
|
| 2019-05-08 |
详情>>
业绩披露：
2018年一季报每股收益-2.36美元,归母净利润-1976.7万美元,同比去年增长7.26%
|
| 2019-05-08 |
详情>>
业绩披露：
2019年一季报每股收益-2.12美元,归母净利润-2202.8万美元,同比去年增长-11.44%
|
| 2019-04-01 |
详情>>
业绩披露：
2018年年报每股收益-9.07美元,归母净利润-7971.4万美元,同比去年增长-20.05%
|
| 2019-03-06 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2019-01-22 |
股东大会：
将于2019-02-22召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding common stock at a ratio not less than 1-for-5 and not greater than 1-for-10 (inclusive), with the exact ratio to be set as a whole number within that range at the discretion of our board of directors before February 22, 2020 without further approval or authorization of our stockholders. The board of directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by our stockholders, in its sole discretion.
2.To transact such other business as may properly come before the special meeting, or any adjournment or postponement thereof.
|
| 2018-11-13 |
股东大会：
将于2018-12-21召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Endologix, Inc. Amended and Restated 2015 Stock Incentive Plan to increase the total number of shares of our common stock reserved for issuance under the plan by 6,000,000 shares, or from 10,300,000 shares to 16,300,000 shares;
2.To transact such other business as may properly come before the special meeting, or any adjournment or postponement thereof.
|
| 2018-11-08 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-0.64美元,归母净利润-5375.9万美元,同比去年增长-3.62%
|
| 2018-08-09 |
详情>>
业绩披露：
2018年中报每股收益-0.52美元,归母净利润-4364.3万美元,同比去年增长-16.05%
|
| 2018-04-17 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1.To elect one director nominee to serve as a Class II director for a three-year term expiring at the annual meeting of stockholders in 2021, and until his successor is duly elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice;
3.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
4.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of our common stock by 35,000,000 shares, or from 135,000,000 shares to 170,000,000 shares;
5.To approve amendments to our Endologix, Inc. 2015 Stock Incentive Plan to, among other things, increase the total number of shares of our common stock reserved for issuance under the plan by 500,000 shares, or from 9,800,000 shares to 10,300,000 shares;
6.To approve the adoption of a stock option exchange program, as described in the proxy statement accompanying this notice;
7.To transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2017-05-01 |
股东大会：
将于2017-05-31召开股东大会
会议内容 ▼▲
- 1. To elect the two director nominees named in the proxy statement accompanying this notice to serve as Class I directors for a three-year term expiring at the annual meeting of stockholders in 2020 or until their successors are duly elected and qualified;
2. To approve by advisory vote the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice;
3. To recommend by advisory vote the frequency of future advisory votes on the compensation of our named executive officers;
4. To approve an amendment to the Endologix, Inc. 2015 Stock Incentive Plan to increase the total number of shares of common stock reserved for issuance thereunder by 3,500,000 shares, or from 6,300,000 shares to 9,800,000 shares;
5. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
6. To transact such other business as may properly come before the annual meeting or any adjournment(s) or postponement(s) thereof.
|
| 2016-05-02 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1.To vote upon a proposal to elect three Class III members, each for a term of three years;
2.To vote upon a “Say-on-Pay” advisory vote on the approval of the compensation of our named executive officers as disclosed in the accompanying proxy statement;
3.To vote upon a proposal to amend the Endologix, Inc. 2015 Stock Incentive Plan to increase the total number of shares of common stock reserved for issuance thereunder from 3,500,000 to 6,300,000;
4.To vote upon a proposal to amend the Endologix, Inc. Amended and Restated 2006 Employee Stock Purchase Plan to increase the total number of shares of common stock reserved for issuance thereunder from 3,058,734 to 4,558,734;
5.To vote upon an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 135,000,000;
6.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
7.To transact such other business as may properly come before the annual meeting or any adjournment(s) or postponement(s) thereof.
|
| 2015-04-17 |
股东大会：
将于2015-05-28召开股东大会
会议内容 ▼▲
- 1.To elect John McDermott and Guido Neels to serve as the Class II members of our board of directors for a term of three years, expiring upon the 2018 annual meeting of stockholders, and until their respective successors are duly elected and qualified;
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement;
3.To approve our 2015 Stock Incentive Plan;
4.To approve an amendment to our Amended and Restated 2006 Employee Stock Purchase Plan to increase the total number of shares purchasable thereunder by 500,000 shares, or from 2,558,734 shares to 3,058,734 shares;
5.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
6.To transact such other business as may properly come before the annual meeting or any adjournment(s) or postponement(s) thereof.
|
| 2014-04-18 |
股东大会：
将于2014-05-22召开股东大会
会议内容 ▼▲
- 1. To elect Daniel Lemaitre to serve as the Class I member of our board of directors for a term of three years, expiring upon the 2017 annual meeting of stockholders, and until his successor is duly elected and qualified;
2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement;
3. To amend our amended and restated certificate of incorporation to increase the number of authorized shares of our common stock thereunder from 75,000,000 to 100,000,000 and to increase the total number of authorized shares of our capital stock from 80,000,000 to 105,000,000;
4. To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014;
5. To transact such other business as may properly come before the annual meeting or any adjournment(s) or postponement(s) thereof.
|
| 2013-04-26 |
股东大会：
将于2013-05-23召开股东大会
会议内容 ▼▲
- 1. To elect Gregory D. Waller, Thomas C. Wilder, III, and Thomas F. Zenty, III to serve as Class III members of our board of directors for a term of three years, expiring upon the 2016 annual meeting of stockholders, and until their successors are duly elected and qualified;
2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement;
3. To approve amendments to our 2006 Stock Incentive Plan to (a) increase the number of shares of our common stock reserved for issuance under the plan by 2,500,000 shares, or from 8,514,478 shares to 11,014,478 shares, (b) change the number of shares under the plan that may be granted as incentive stock options from 8,514,478 shares to 11,014,478 shares and (c) insert a fungible counting provision whereby the number of shares of available for grant under the plan will be reduced by one-and-six-tenths (1.6) shares for each share granted pursuant to a restricted stock or restricted stock unit award;
4. To approve our Amended and Restated 2006 Employee Stock Purchase Plan and an amendment thereto to increase the total number of shares purchasable thereunder by 500,000 shares, or from 2,058,734 shares to 2,558,734 shares;
5. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013;
6. To transact such other business as may properly come before the annual meeting or any adjournment(s) or postponement(s) thereof.
|